Furthermore, the combined treatment of AML cells with ZEN-3365 and GANT-61 resulted in significantly reduced cell growth and colony formation capacity compared to the single-agent treatment, leading to the conclusion that BRD4 inhibition with ZEN-3365 represents a promising strategy for rational combinatorial AML therapy. This evidence concerns the gene BRD4 and acute myeloid leukemia.